A Double-Blind, Randomized, Placebo-Controlled, Two-Period, Cross-Over Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma.
Phase of Trial: Phase I/II
Latest Information Update: 25 Feb 2015
At a glance
- Drugs N 6022 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors N30 Pharma
- 21 Feb 2012 Actual patient number (14) added as reported by ClinicalTrials.gov.
- 21 Feb 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 21 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.